Table 3 Adverse events related to the canfosfamide and pegylated liposomal doxorubicin combination (NCI-CTC v2.0) (N = 39)
| Â | Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) |
|---|---|---|---|---|
Hematologic (All Patients) | Â | Â | Â | Â |
   Anemia | 9 (23.1) | 21 (53.8) | 5 (12.8) | 1 (2.6) |
   Leucopenia | 3 (7.7) | 13 (33.3) | 15 (38.5) | 2 (5.1) |
   Neutropenia | 0 (0.0) | 8 (20.5) | 12 (30.8) | 11 (28.2) |
   Thrombocytopenia | 10 (25.6) | 5 (12.8) | 10 (25.6) | 0 (0.0) |
   Leukocytosis | 8 (20.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
   Febrile Neutropenia | 0 (0.0) | 0 (0.0) | 2 (5.1) | 0 (0.0) |
Non-hematologic (≥ 5% of patients) |  |  |  |  |
   Nausea | 9 (23.1) | 20 (51.3) | 6 (15.4) | 0 (0.0) |
   Fatigue | 1 (2.6) | 11 (28.2) | 20 (51.3) | 1 (2.6) |
   Vomiting | 10 (25.6) | 8 (20.5) | 4 (10.3) | 0 (0.0) |
   Rash | 8 (20.5) | 12 (30.8) | 3 (7.7) | 0 (0.0) |
   Diarrhea | 1 (2.6) | 6 (15.4) | 3 (7.7) | 0 (0.0) |
   Drug Hypersensitivity | 1 (2.6) | 1 (2.6) | 1 (2.6) | 0 (0.0) |
   Infusion Site Pain | 4 (10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
   Pyrexia | 2 (5.1) | 2 (5.1) | 0 (0.0) | 0 (0.0) |
   Dysuria** | 1 (2.6) | 1 (2.6) | 0 (0.0) | 0 (0.0) |
   Stomatitis* | 4 (10.3) | 16 (41.0) | 1 (2.6) | 0 (0.0) |
   PPE Syndrome* | 3 (7.7) | 10 (25.6) | 6 (15.4) | 0 (0.0) |
   Mucosal Inflammation* | 8 (20.5) | 11 (28.2) | 0 (0.0) | 0 (0.0) |
   Alopecia* | 16 (41.0) | 1 (2.6) | 0 (0.0) | 0 (0.0) |
   Neuropathy* | 3 (7.7) | 2 (5.1) | 2 (5.1) | 0 (0.0) |
   Pain in Extremity* | 2 (5.1) | 3 (7.7) | 3 (7.7) | 0 (0.0) |
   Erythema* | 5 (12.8) | 2 (5.1) | 0 (0.0) | 0 (0.0) |
   Dry Skin* | 2 (5.1) | 2 (5.1) | 0 (0.0) | 0 (0.0) |
   Pruritus* | 3 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
   Gingivitis* | 1 (2.6) | 1 (2.6) | 0 (0.0) | 0 (0.0) |
   Dermatitis* | 0 (0.0) | 1 (2.6) | 1 (2.6) | 0 (0.0) |
   Pigmentation Disorder* | 1 (2.6) | 1 (2.6) | 0 (0.0) | 0 (0.0) |
   Flushing* | 2 (5.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |